Prot #M15-330: A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3